Cargando…
Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis
Background: A growing number of evidences suggest that TMZ applications can generate impressive benefits for APT and PC patients. However, the definite role of TMZ for individuals remains unclarified due to the variation between studies. And the predictive factors to alter its efficacy remain debata...
Autores principales: | Luo, Mei, Tan, Yiheng, Chen, Wenli, Hu, Bin, Wang, Zongming, Zhu, Diming, Jiao, Haosen, Duan, Chengbin, Zhu, Yonghong, Wang, Haijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250148/ https://www.ncbi.nlm.nih.gov/pubmed/34220696 http://dx.doi.org/10.3389/fneur.2021.700007 |
Ejemplares similares
-
Prediction of the Recurrence of Non-Functioning Pituitary Adenomas Using Preoperative Supra-Intra Sellar Volume and Tumor-Carotid Distance
por: Chen, Wenli, et al.
Publicado: (2021) -
Temozolomide in aggressive pituitary adenomas and carcinomas
por: Ortiz, Leon D., et al.
Publicado: (2012) -
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain
por: Lamas, Cristina, et al.
Publicado: (2023) -
SUN-272 Significant Response to Temozolomide in Two Aggressively Growing Pituitary Adenomas
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2020) -
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas
por: Das, Liza, et al.
Publicado: (2021)